The US is the bigger Epilepsy Drugs market: $4 Bn against $175 Mn in 2023, about 23 times as large.
India grows faster: 6.5% a year, against 1.5%. The gap still grows from $3.9 Bn to $4.4 Bn by 2033.
Clinical research: 224 active trials in the US, 4 in India.
| Measure |  US |  India |
|---|---|---|
| Market size, 2023 | $4 Bn | $175 Mn |
| Market size, 2033 projected | $4.7 Bn | $328 Mn |
| Growth a year (CAGR) | 1.5% | 6.5% |
| Money added, 2023–2033 | $647 Mn | $153 Mn |
| Share of the world market | 42% | 1.8% |
| Size rank of 24 countries | #1 | #12 |
| Market per person, 2023 | $12 | $0.12 |
| Active clinical trials | 224 | 4 |
| Full report | US report | India report |
Year by year, 2023 to 2033
US India · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Epilepsy Drugs, US or India?
The US is the bigger Epilepsy Drugs market: $4 Bn against $175 Mn in 2023, about 23 times as large.
Which grows faster in Epilepsy Drugs, US or India?
India grows faster: 6.5% a year, against 1.5%. The gap still grows from $3.9 Bn to $4.4 Bn by 2033.
More Epilepsy Drugs comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.